BIMZELX® Demonstrates Sustained Inflammation Control
BIMZELX® (bimekizumab-bkzx) three-year rheumatology data presented at ACR 2025 showed sustained inflammation control in psoriatic arthritis and axial spondyloarthritis.
Key Findings
- Sustained improvements in psoriatic arthritis (PsA) patients across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis.
- Half of patients with axial spondyloarthritis (axSpA) maintained a clinical response to stringent endpoints from Week 16 to three years, with 50% never losing ASDAS low disease activity (LDA) (<2).
No direct quote available in the provided text.
Author's summary: BIMZELX® shows sustained inflammation control in PsA and axSpA patients.
More News
- Training microbes to speak the molecular code of healing
- Smarter decisions, better outcomes: How a new molecular test improves patient care
- Defense Specialist Hensoldt Secures Key Contracts and Technological Milestones () | aktiencheck.de
- All-new 2026 Proton Saga revealed in full at the 47th ASEAN Summit
- Banging bumper fun from 2000AD!
- Biotech Stock Surges as Regulatory Decision Nears () | aktiencheck.de
- Winter skincare tips: 10 easy remedies to treat dry and itchy skin
- Time for Action: Investing in Health Canada to Accelerate Access to…
- Kaishan signs steam supply agreement for 165-MW geothermal green ammonia facility in Kenya
- Second Prototype of China’s J-36 Uncovered with Notable Structural Changes